EASL 2012: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C patients, with favorable safety and efficacy among people with liver cirrhosis, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL 2012: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
- Details
- Category: HCV Treatment
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) this week in Barcelona.
EASL 2012: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients
- Details
- Category: HCV Treatment
- Published on Friday, 27 April 2012 00:00
- Written by Keith Alcorn
Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naive patients presented last week at the 47th International Liver Congress (EASL 2012) in Barcelona.
EASL 2012: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy
- Details
- Category: HCV Treatment
- Published on Friday, 27 April 2012 00:00
- Written by Michael Carter
A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40% and 68% in patients who did not respond to a previous course of hepatitis C therapy, data presented to the 47th International Liver Congress (EASL 2012) in Barcelona last week show.
EASL 2012: GS-7977 with Interferon/Ribavirin Cures Most Treatment-Naive Hepatitis C Patients in 12 Weeks
- Details
- Category: HCV Treatment
- Published on Friday, 27 April 2012 00:00
- Written by Liz Highleyman
Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
More Articles...
- EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Complete Coverage of the 2012 International Liver Congress
- EASL 2012: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- EASL 2012: Boceprevir Improves Cure Rates for HIV/HCV Coinfection but Beware of Drug Interactions
Web Design and Development by